Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20944694 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL20944530 | 0.93 | KDM4E (0.51) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL20944532 | 0.93 | KDM4E (0.51) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL24163448 | 0.83 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL20944746 | 0.81 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL20944758 | 0.81 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL20944749 | 0.81 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL21834930 | 0.80 | MAPK1 (0.58) | MEN1KMT2A | |
| SCHEMBL20944673 | 0.78 | KMT2A (0.58) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1579576 | 0.76 | GAA (0.48) | ALDH1A1MEN1KMT2AKDM4EDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 2307/4885MEN1 4238/4885KMT2A 967/4885 |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | JAK2, JAK1, JAK3 | ALDH1A1 2307/4885MEN1 4238/4885KMT2A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.